BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 5, 2021

Primary Completion Date

August 1, 2025

Study Completion Date

December 1, 2025

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Ipilimumab

1mg/kg IV on day 1 (1 dose total)

DRUG

Nivolumab

3mg/kg (to a maximum of 240mg) IV on days 1, 15, 29 (+/- 3 days) (3 doses total)

RADIATION

SBRT

1 fraction or 2 fractions delivered to the gross primary tumor and nodal disease, following the first treatment with ipilimumab + nivolumab on days 1-3.

Trial Locations (1)

02903

RECRUITING

Rhode Island Hospital, Providence

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Brown University

OTHER